Alto Neuroscience (NYSE:ANRO) Price Target Raised to $41.00 at Robert W. Baird

Alto Neuroscience (NYSE:ANRO) had its target price lifted by Robert W. Baird from $22.00 to $41.00 in a research note released on Wednesday,Benzinga reports. The brokerage currently has an outperform rating on the stock.

Several other research firms have also commented on ANRO. Weiss Ratings reissued a “sell (e+)” rating on shares of Alto Neuroscience in a research report on Monday, December 29th. Chardan Capital reaffirmed a “buy” rating and issued a $30.00 price target on shares of Alto Neuroscience in a report on Tuesday. BTIG Research upped their price objective on Alto Neuroscience from $27.00 to $28.00 and gave the company a “buy” rating in a research note on Tuesday, February 17th. Jefferies Financial Group reaffirmed a “buy” rating and set a $35.00 target price on shares of Alto Neuroscience in a report on Monday. Finally, Wedbush lifted their target price on Alto Neuroscience from $13.00 to $22.00 and gave the stock a “neutral” rating in a research report on Tuesday. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Alto Neuroscience currently has a consensus rating of “Moderate Buy” and a consensus price target of $34.33.

Alto Neuroscience Trading Up 0.9%

NYSE:ANRO opened at $22.56 on Wednesday. The business’s 50-day moving average is $18.25 and its two-hundred day moving average is $13.41. The firm has a market capitalization of $720.79 million, a PE ratio of -10.35 and a beta of 2.52. Alto Neuroscience has a 12 month low of $1.60 and a 12 month high of $25.17. The company has a debt-to-equity ratio of 0.12, a current ratio of 15.69 and a quick ratio of 15.42.

Alto Neuroscience (NYSE:ANRO) last issued its earnings results on Thursday, March 19th. The company reported ($0.45) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.11. Research analysts predict that Alto Neuroscience will post -2.54 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Bank of Montreal Can acquired a new stake in Alto Neuroscience during the 2nd quarter worth about $25,000. AlphaCore Capital LLC boosted its position in Alto Neuroscience by 100.0% during the 2nd quarter. AlphaCore Capital LLC now owns 20,000 shares of the company’s stock worth $44,000 after acquiring an additional 10,000 shares during the period. AQR Capital Management LLC purchased a new position in Alto Neuroscience during the 1st quarter valued at about $52,000. Torren Management LLC acquired a new position in shares of Alto Neuroscience in the 4th quarter valued at about $62,000. Finally, Invesco Ltd. acquired a new position in shares of Alto Neuroscience in the 1st quarter valued at about $67,000.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.